1. Home
  2. JZXN vs INDP Comparison

JZXN vs INDP Comparison

Compare JZXN & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

JZXN

Jiuzi Holdings Inc.

HOLD

Current Price

$1.04

Market Cap

2.0M

ML Signal

HOLD

Logo Indaptus Therapeutics Inc.

INDP

Indaptus Therapeutics Inc.

HOLD

Current Price

$1.86

Market Cap

4.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JZXN
INDP
Founded
2019
2000
Country
China
United States
Employees
N/A
N/A
Industry
Retail-Auto Dealers and Gas Stations
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0M
4.5M
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
JZXN
INDP
Price
$1.04
$1.86
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
1.7M
19.8K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
12.02
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.12
$0.27
52 Week High
$8.50
$13.24

Technical Indicators

Market Signals
Indicator
JZXN
INDP
Relative Strength Index (RSI) 43.07 48.42
Support Level $0.84 $1.65
Resistance Level $1.19 $2.18
Average True Range (ATR) 0.19 0.16
MACD -0.02 0.01
Stochastic Oscillator 31.53 48.71

Price Performance

Historical Comparison
JZXN
INDP

About JZXN Jiuzi Holdings Inc.

Jiuzi Holdings Inc operates as a franchise under the brand name Jiuzi. It sells new energy vehicles in third-fourth tier cities in China. The firm also sells plug-in electric vehicles on demand from vehicle buyers. Its operating segments are propretaey product; and resale of sourced Equipment and accessories from third party products. The company generates a majority of its revenue from the propretaey product segment. Geographically, the firm operates in China.

About INDP Indaptus Therapeutics Inc.

Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.

Share on Social Networks: